Navigation Links
Potential viral therapy weapon for difficult cancers is safe and effective in study
Date:4/22/2008

normally occurring gene was deleted and replaced with a gene that encodes an enzyme to activate chemotherapy drugs called oxazophosphorines, including cyclophosphamide (CPA). Previous studies have reported the rRp450 virus kills cancer cells by causing their cell membranes to erupt, and that the virus helps the anti-tumor effects of CPA. In the current study, rRp450/CPA treatment significantly shrunk a form of human rhabdomyosarcoma, a relatively rare and aggressive tumor that wraps around muscles and soft tissues, usually in younger children. When the grafted tumors reached 200-500mm in size, seven mice were treated twice over eight days with a combination of rRp450/CPA, with rRp450 administered by direct tumor injection 24 hours prior to CPA. The researchers noted significant tumor shrinkage with one animal perishing 20 days following initial injection, two more within 30 days, two within 40 days and the last two mice surviving nearly 50 days post treatment.

The investigators also confirmed the anti-tumor effect of rRp450 treatment alone in mouse models of human cancers rhabdomyosarcoma and neuroblastoma, where they observed significant tumor shrinkage in 13 of 13 injected tumors. Treatment with CPA alone in these models showed limited anti-tumor effectiveness. In a control group of tumor-carrying mice treated with a placebo, all died within 10 days of injection.

Also noteworthy in this study is documentation of the treatments potential safety, specifically toxicity to nerve tissues. Most research of oncolytic herpes simplex viruses (oHSVs) has so far been limited to those engineered by deleting both copies of the neurovirulence gene that prompts wild-type HSV-1 virus to spread and invade the nervous system. Deleting both copies disarms most of the virus disease-spreading properties while retaining its ability to damage targeted cancer cells. The rRp450 virus is different because it retains both copies of the virulence gene but is attenuated by d
'/>"/>

Contact: Nick Miller
513-803-6035
Cincinnati Children's Hospital Medical Center
Source:Eurekalert

Page: 1 2 3 4

Related medicine news :

1. Penn researchers find potential in yeast for selecting Lou Gehrigs disease drugs
2. Minnesota partnership advances potential MS therapy
3. Toxic Stock Syndrome Report: Many Companies Are Keeping Shareholders in the Dark on Potential Recalls, Bans, and Other Risks
4. A potential sugar fix for tumors
5. Potential blood test for chronic sinusitis identified
6. Medical errors cost US $8.8B, result in 238,337 potentially preventable deaths: HealthGrades study
7. Stem cell research leads to potential new therapy for rare blood disorder
8. New research shows benefits of ultrasound contrast agents outweigh potential risk to heart patients
9. Angina drug potentially useful against heart rhythm disorders
10. Neuronal regulators offer potential targets for cancer
11. Companies Not Fully Tapping Potential of Onsite Health Centers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... MA (PRWEB) December 15, 2014 ... management solutions, announced today that it has received ... Quality Assurance (NCQA) for its Disease Management (DM) ... pulmonary disease (COPD), coronary heart disease and diabetes. ... from NCQA for Health Dialog’s Disease Management (DM) ...
(Date:12/15/2014)... The increase in prevalence of disabling hearing loss in the ... contributing to the growth in the global audiological market. Devices ... loss and balance disorders are known as audiological devices. An ... amplifier. The global market is expected to grow at a ... 2014 to 2019. Some of the factors which are driving ...
(Date:12/15/2014)... In support of high-quality independent peer ... state laws that may have unintended consequences through ... of public health policy. , The position paper, ... Independent Review, contends that state legislation that restricts ... determinations can result in subpar outcomes for both ...
(Date:12/15/2014)... Kenmode Precision Metal Stamping has announced ... of Quality Assurance. He brings more than 15 ... certifications for manufacturers in the U.S. and abroad. ... Manager at Sonoco Products Company in the Protective Solutions ... Quality Assurance Manager for Prince Industries, all in the ...
(Date:12/15/2014)... Colorado (PRWEB) December 15, 2014 Following ... Friday sales, The Grass Station is gearing up for ... one of Colorado’s oldest and largest marijuana dispensaries, began ... sales event that ran through Thanksgiving weekend. , ... then; people are excited,” says Grass Station CEO and ...
Breaking Medicine News(10 mins):Health News:Health Dialog Receives NCQA Accreditation for Disease Management Programs 2Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 2Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 3Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 4Health News:NAIRO Calls for Higher Quality Independent Peer Review By Ending Restrictive State Laws 2Health News:Kenmode Precision Metal Stamping Appoints Abid Rashid as Director of Quality Assurance 2Health News:Colorado’s Grass Station Helps Holiday Shoppers Put Something Special under the Christmas Tree 2
... for individual women in crisis, but advance access to emergency ... pregnancy. ,Contrary to the fears of critics, ... behavior. ,,According to a new review of studies, ... for emergency contraception had an equal chance of becoming pregnant ...
... what many doctors are not aware of is the fact that ... , The research based on around 250 ... Australia showed that many men; ‘straight and happily married’, do ... up as transmitters of HIV/AIDS to their unsuspecting wives, and non-infected ...
... Clinic researchers have designed a new strategy in the promising ... in boosting T cells -- the immune builders akin to ... strategy may prove to be more successful than methods currently ... which was lost to Hurricane Katrina but recovered at Mayo ...
... called upon MPs to support the newly amended Mental Health ... balance between safeguarding patients’ rights as well as ... for the bill, stating that it will serve to bring ... patients. ,As the bill goes to the House ...
... Children of all ages are exposed to TV commercials for junk foods ... study released by the US Kaiser Family Foundation found that children between ... an average of 21 a day or more than 7,600 per year. ... per day or over 6,000 a year, while children aged two to ...
... As researchers from the University of North Carolina mulled ... //have found out that the rhythmic motion of the ... material from the lungs. ,The research published ... could change existing treatment methods for cystic fibrosis. When ...
Cached Medicine News:Health News:Emergency Contraception Does Not Reduce Unintended Pregnancy Rate 2Health News:Emergency Contraception Does Not Reduce Unintended Pregnancy Rate 3Health News:Sleeping With The Enemy 2Health News:Breast Cancer Vaccine Stimulates Potent Immune Response to Cancer Cells 2Health News:Breast Cancer Vaccine Stimulates Potent Immune Response to Cancer Cells 3Health News:Breast Cancer Vaccine Stimulates Potent Immune Response to Cancer Cells 4Health News:Ever-Controversial Mental Health Act To Be Decided Upon 2
(Date:12/15/2014)... Norway , December 15, 2014 ... innovative drugs for aggressive drug resistant cancers, today announces ... in a private placing from new and existing investors. ... financing to support the development of its pipeline of ... program for its lead drug candidate, BGB324, a first-in-class ...
(Date:12/15/2014)... , December 15, 2014 Investor-Edge ... ZGNX ), Eli Lilly and Company (NYSE: ... Sanofi (NYSE: SNY ), and Novartis AG (NYSE: ... can be accessed at: http://investor-edge.com/register . On ... down 1.16%, the Dow Jones Industrial Average lost 1.79%, to ...
(Date:12/15/2014)... BOSTON , December 15, 2014 ... discovery and development company, is pleased to announce the ... United States relating to its GPCR-focused drug ... US significantly strengthens the global patent estate covering Heptares, ... The suite of patents recently granted by the ...
Breaking Medicine Technology:BerGenBio Completes NOK90 Million Fundraising 2Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 2Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 3Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 4Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 5Heptares Extends Global Patent Protection for GPCR-Focused Drug Discovery Platform With Grant of Core Patents in the United States 2
... Risk Frontline Elderly AML and in Combination with Cytarabine in Relapsed/Refractory ... for Tuesday, December 9 at 11:00 am ET to Discuss Phase ... , SAN FRANCISCO , Dec. 7 Sunesis ... of new data from two ongoing clinical trials demonstrating that the ...
... Dec. 6 Results from RESTORE 2, a,placebo-controlled, Phase ... the number of seizures in adult,patients with refractory partial-onset ... added to a patient,s current anti-epileptic drug (AED) therapy. ... experiencing,seizures despite taking stable doses of up to three ...
Cached Medicine Technology:Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology 2Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology 3Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology 4Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology 5Sunesis Pharmaceuticals Announces Presentation of Voreloxin Clinical Data in Patients with Acute Myeloid Leukemia at the 50th Annual Meeting of the American Society of Hematology 6Retigabine Significantly Reduces the Number of Seizures in Adults With Inadequately Controlled Partial-Onset Epilepsy 2Retigabine Significantly Reduces the Number of Seizures in Adults With Inadequately Controlled Partial-Onset Epilepsy 3Retigabine Significantly Reduces the Number of Seizures in Adults With Inadequately Controlled Partial-Onset Epilepsy 4Retigabine Significantly Reduces the Number of Seizures in Adults With Inadequately Controlled Partial-Onset Epilepsy 5
The Cellabs Rapimal (P.f.) is a rapid and sensitive in vitro immunochromatography assay system for the detection of HRP-2 antigen produced by P. falciparum at the merozoite (red blood cell) stage o...
192 Test HRP-II Enzyme Immunoassay for the presence of Plasmodium falciparum infection....
Malaria device / strip (2 line, PAN specific-pLDH)...
... Uni-Gold™ Pf Malaria Test is a ... presence of Plasmodium falciparum ... an antigen-capture assay detecting presence of ... protein II (PfHRP- II), which is ...
Medicine Products: